Research · 3 min read
One Molecule, Two Brand Names, Two Different Labels
Semaglutide is sold as Ozempic and as Wegovy. The two are approved for different things, in different people, at different ages. A page that says only "semaglutide" has not told you which one it means.
Key takeaways
- FDA approves a product for a use in a population, not a molecule in the abstract — so two brands of one active ingredient can carry two different labels.
- Ozempic's glycemic indication names adults with type 2 diabetes; Wegovy's weight indication reaches pediatric patients aged 12 and older with obesity. Same active ingredient, different approvals.
- Across the three labels read here the ages differ three ways: adults, 10 and older, and 12 and older — each tied to one indication on one label.
- A compounded preparation carries no FDA-approved indication, so indication language on a page selling one was borrowed from a product that is not in the box.
- A brand-name figure and a compounded figure are quotes for two different products, not two quotes for the same one.
- A page mixing diabetes, weight, kidney and liver claims has combined labels that do not describe a single product.
Answer first: an approval belongs to a product, not to a molecule
FDA approves a product for a use in a population. It does not approve a chemical in the abstract. So the same active ingredient, marketed under two brand names by the same company, can carry two labels that do not say the same thing — and neither label's claims transfer to the other.
Semaglutide is the clearest case. Ozempic's label states it is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus," plus cardiovascular-risk and kidney-outcome indications in adults with type 2 diabetes. Wegovy's label, for the same active ingredient, states a weight indication — "to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity; adults with overweight in the presence of at least one weight-related comorbid condition" — plus a cardiovascular indication and one for noncirrhotic MASH.
Read those side by side and the differences are not cosmetic. One is a diabetes product; the other is a weight-management product. One names adults only in its glycemic indication; the other reaches age 12 for obesity. One carries a kidney-outcome indication; the other carries a liver-disease indication. Same molecule.
The ages are not the same either, and not only across brands
Mounjaro, whose active ingredient is tirzepatide, states that it is indicated "as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus," together with a cardiovascular-risk indication in adults with type 2 diabetes at high risk.
So across these three documents there are three different age boundaries: adults only for Ozempic's glycemic indication, 10 and older for Mounjaro's, and 12 and older for Wegovy's obesity criterion. None of them is the general answer to "how old do you have to be" — each belongs to one indication on one label.
An age quoted without its indication and its product cannot be checked, and it is a common way for a true number to end up attached to a false claim.
Why a seller's page usually says only the molecule
A telehealth page selling a compounded preparation typically names the active ingredient rather than a brand, and there is a straightforward reason: a compounded preparation is not the approved product. It is not Ozempic and it is not Wegovy. It has no FDA-approved indication of its own, because compounded preparations do not carry approved indications at all.
That makes the molecule name the only accurate thing such a page can put on it — and it also means any indication language borrowed from a brand label has been borrowed from a product the page is not selling. A claim about what semaglutide is approved to treat is a claim about Ozempic or about Wegovy, and neither is in the box.
This site's separate article on the two federal lists that decide what a pharmacy may compound covers that boundary in full. The point here is narrower: brand names carry approvals, and molecule names do not.
What this changes when you compare offers
When two sellers both advertise semaglutide, they may be describing materially different things — a compounded preparation, a brand-name product dispensed through a pharmacy, or a program that switches between them. This site records a brand route separately from a compounded one for exactly that reason.
It also means a price comparison can be a comparison of unlike items. A brand-name figure and a compounded figure are not two quotes for one product; they are quotes for two different products, one of which has an FDA-approved label behind it and one of which does not.
And it explains a mismatch readers notice constantly: a marketing page describing diabetes benefits while selling a weight program, or the reverse. Those benefits sit on two different labels, and no single product carries both sets.
How to check which product a page means
Look for a brand name. If the page names one, the label for that brand states what it is approved for, is public, and carries a revision date on its own face — the three read for this article are dated 5/2026, 6/2026 and 8/2026.
If the page names only a molecule, ask whether the product is compounded. If it is, no approved indication attaches to it, and any indication language on the page came from somewhere else.
Then match the claim to the label that actually carries it. A weight claim belongs to a weight label; a glycemic claim belongs to a diabetes label; a kidney or liver claim belongs to the specific label that states it. A page that mixes them has combined documents that do not describe one product.
Sources
- OZEMPIC (semaglutide) injection — full prescribing informationThe quoted glycemic indication "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus"; the presence of a cardiovascular-risk indication in adults with type 2 diabetes and established cardiovascular disease; and the presence of an indication covering sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Also supports that this label's glycemic indication names adults and no younger age.
- WEGOVY (semaglutide) injection — full prescribing informationThe quoted weight indication naming "adults and pediatric patients aged 12 years and older with obesity" and, as a separate criterion, "adults with overweight in the presence of at least one weight-related comorbid condition"; and the presence on the same label of a cardiovascular-risk indication and an indication for noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
- MOUNJARO (tirzepatide) injection — full prescribing informationThe quoted glycemic indication "as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus", which is the source of the age 10 stated here; and the presence of a cardiovascular-risk indication in adults with type 2 diabetes at high risk for those events. This citation supports the indications described here, not storage, in-use time or freezing instructions.
Frequently asked questions
Are Ozempic and Wegovy the same drug?
They share an active ingredient, semaglutide, and they carry different approvals. Ozempic's label states a glycemic indication in adults with type 2 diabetes plus cardiovascular and kidney-outcome indications; Wegovy's states a weight indication reaching age 12 for obesity, plus cardiovascular and MASH indications. An approval belongs to a product, not to a molecule.
Does one label's indication apply to the other product?
No. Each approval was granted for a specific product on specific evidence. Claims do not transfer between two brands because they share an active ingredient.
What is the youngest age named in these labels?
Of the three read for this article, Mounjaro's glycemic indication names "adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus." Wegovy's obesity criterion names 12 and older. Ozempic's glycemic indication names adults. Each age belongs to one indication on one label.
Does a compounded semaglutide product have an approved indication?
No. Compounded preparations do not carry FDA-approved indications. Any indication language on a page selling one has been taken from a brand-name product that is not what is being sold.
Why do sellers write the molecule name instead of a brand?
Because for a compounded preparation the molecule name is the accurate description — it is not the approved brand product. That is a correct label for what is sold, and it is also why brand-label claims do not follow it.
Does this article cover every brand of these molecules?
No. This article compares the September 2026 labeling for Ozempic, Wegovy and Mounjaro. It does not cover the separate tirzepatide weight-management brand or every product containing these ingredients.